Immunosuppressive Treatment for Inflammatory Dilated Cardiomyopathy (Myocarditis)

  • B. Maisch
  • G. Hufnagel
  • S. Pankuweit
  • M. Herzum
  • U. Schönian
  • C. Bethge
  • I. Portig
  • A. Wilke
Conference paper


Controversy still exists on whether immusuppressive treatment is beneficial in myocarditis. This contribution examines the immunologic rationale for immunosuppressive therapy in inflammatory dilated cardiomyopathy by revisiting currently available data in man and experimental animals.


Major Histocompatibility Complex Class Dilate Cardiomyopathy Immunosuppressive Treatment Endomyocardial Biopsy Viral Myocarditis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    WHO/ISFC task force (Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connel J, Olsen E, Thien G, Goodwin J, Gyarfas I, Martin I, Nordet P) (1996) Report of the 1995 World Health Organization/Inernational Society andFederation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93:841–842PubMedCrossRefGoogle Scholar
  2. 2.
    Levine HD (1979) Virus myocarditis: a critique of the literature from clinical, electrocardiographic and pathological stand-points. Am J Med Sci 277:132–143PubMedCrossRefGoogle Scholar
  3. 3.
    Maisch B, Salzer E, Ertl G, Kochsiek K (1987) Pericardial thickness and pericardial effusion as echocardiographic markers of acute or past pericardial, perimyocardial and myocardial disease. Eur Heart J 8 [Suppl J]:109–114CrossRefGoogle Scholar
  4. 4.
    Maisch B, Drude L (1991) Pericardioscopy-a new diagnostic tool in inflammatory disease of the pericardium. Eur Heart J 12 [Suppl D]:2–6PubMedCrossRefGoogle Scholar
  5. 5.
    Maisch B, Drude L (1992) Epi-and pericardial biopsy by pericardioscopy. Circulation 82 [Suppl 3]:417 (A1658)Google Scholar
  6. 6.
    Aretz HT, Billingham ME, Edwards WD et al (1986) Myocarditis-a histopathologic definition and classification. Am J Cardiovasc Pathol 1:3–14Google Scholar
  7. 7.
    Doerr W (1956) Morphologie der Myokarditis. Verh Dtsch Ges Inn Med 77:301–335CrossRefGoogle Scholar
  8. 8.
    Shanes JG, Gahli J, Billingham ME et al (1987) Interobserver variability in the pathological interpretation of endomyocardial biopsy results. Circulation 75:401–405PubMedCrossRefGoogle Scholar
  9. 9.
    Hahn EA, Hartz VL, Moon TE, O’Connel JB, Herskowitz A, McManus BM, Mason JW for the Myocarditis Treatment Trial Investigators (1995) The Myocarditis Treatment Trial: design, methods and patient enrolment Eur Heart J 76 (Suppl):162–167Google Scholar
  10. 10.
    Mason JW, O’Connel JB, Herskowitz A et al (1995) A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 333:0269–275CrossRefGoogle Scholar
  11. 11.
    Maisch B (1986) Immunologic regulator and effector function in perimyocarditis, postmyocarditic heart muscle disease and dilated cardiomyopathy. Basic Res Cardiol 81 [Suppl l]:217–242PubMedGoogle Scholar
  12. 12.
    Maisch B, Bauer E, Hufnagel G, Pfeifer U, Rohkamm R (1988) The use of endomyocardial biopsy in heart failure. Eur Heart J 9 [Suppl H]:59–71PubMedCrossRefGoogle Scholar
  13. 13.
    Kühl U, Schultheiss H-P (1995) Treatment of chronic myocarditis with corticosteroids. Eur Heart J 16 [Suppl O]:168–172PubMedCrossRefGoogle Scholar
  14. 14.
    Maisch B, Hufnagel G, Schönian U, Hengstenberg C for the ESETCID Investigators (1995) The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J 16 [Suppl O]:173–175PubMedCrossRefGoogle Scholar
  15. 15.
    Kühl U, Daun B, Seeberg B, Schultheiss H-P, Strauer BE (1992) Dilated Cardiomyopathy — a chronic myocarditis? Immunohistological characterization of lymphocytic infiltrates. Herz 17:97–106PubMedGoogle Scholar
  16. 16.
    Hershkowitz A, Baughman KL, Rose NR et al (1988) Introduction of major histocompatibility (MHC) antigens on myocardial cells in patients with active myocarditis and idiopathic cardiomyopathy. In: Schultheiß HP, ed. New Concepts in Viral Heart Disease. Springer Verlag, Berlin, Heidelberg, New York; pp 93–104Google Scholar
  17. 17.
    Hufnagel G, Maisch B (1991) Expression of MHC class I and II antigens and the IL-2 receptor in rejection, myocarditis and dilated cardiomyopathy. Eur Heart J 12 [Suppl D]:137–140PubMedCrossRefGoogle Scholar
  18. 18.
    Hengstenberg C, Rose ML, Olsen EGJ, Maisch B (1991) Immune response to the endothelium in myocarditis, dilated cardiomyopathy and rejection after heart transplantation. Eur Heart J 12 [Suppl D]:144–146PubMedCrossRefGoogle Scholar
  19. 19.
    Maisch B, Weyerer O, Hufnagel G, Hengstenberg C, Schönian U, Haverich A, Kochsiek K (1989) The vascular endothelium as target of humoral autoreactivity in myocarditis and rejection. Z Kardiol 78 [Suppl 6]:95–99PubMedGoogle Scholar
  20. 20.
    Bowles NE, Richardson PJ, Olsen EGJ, Archard LC (1986) Detection of coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet I:1120–1123CrossRefGoogle Scholar
  21. 21.
    Kandolf R, Hofschneider PH (1984) Effect of interferon on the replication of coxsackie B3 virus in cultured human foetal heart cells. In: Bolte HD (ed) Viral heart disease. Springer, Berlin-Heidelberg-New York pp 57–63CrossRefGoogle Scholar
  22. 22.
    Kandolf R, Ameis D, Kirchner P, Canu A, Hofschneider PH (1987) In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 84:6272–6276PubMedCrossRefGoogle Scholar
  23. 23.
    Tracy S (1984) A comparison of genomic homologies among the coxsackievirus B group: use of fragments of the cloned coxsackievirus B3 genome as probes. J Gen Virol 65:2167–2172PubMedCrossRefGoogle Scholar
  24. 24.
    Tracy S, Hufnagel G, Chapman N (1992) Interesting problems in enteroviral inflammatory heart disease. Herz 17:79–84PubMedGoogle Scholar
  25. 25.
    Maisch B, Wendl J (1989) Cytomegalovirus DNA in endomycardial biopsies of patients with (peri)myocarditis. Eur Heart J 9[Suppl]:1000 (abstr)Google Scholar
  26. 26.
    Schönian U, Crombach M, Maisch B (1991) Does CMV infection play a role in myocarditis? New aspects from in-situ hybridization. Eur Heart J 12 [Suppl D]:65–99PubMedCrossRefGoogle Scholar
  27. 27.
    Schönian U, Crombach M, Maisch B (1993) Assessment of cytomegalovirus DNA and protein expression in patients with myocarditis. Clin Immunol Immunopathol 68:229–233PubMedCrossRefGoogle Scholar
  28. 28.
    Jin O, Sole MJ, Butany JW, Chia WK, McLaughlin PR, Liu P, Liew CC (1990) Detection of Enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation 82:8–16PubMedCrossRefGoogle Scholar
  29. 29.
    Grasso M, Arbustini E, Silini E, Diegoli M, Percivalle E, Ratti G, Bramerio M, Gavazzi A, Viganò M, Milanesi G (1992) Search for coxsackievirus B3 RNA in idiopathic dilated cardiomyopathy using gene amplification by polimerase chain reaction. Am J Cardiol 69:658–664PubMedCrossRefGoogle Scholar
  30. 30.
    Giacca M, Severini GM, Mestroni L, Salvi A, Lardieri G, Falaschi A, Camerini F (1994) Low frequency of detection of enterovirus RNA in endomyocardial tissue of patients with idiopathic dilated cardiomyopathy by nested polymerase chain reaction. J Am Coll Cardiol 24:10–33CrossRefGoogle Scholar
  31. 31.
    Martin AB, Webber S, Fricker FJ, Jaffe R, Demmler G, Kearney D, Zhang Y-H, Bodurtha J, Gelb B, Ni J, Bricker T, Towbin JA (1994) Acute Myocarditis — Rapid dignosis by PCR in children. Circulation 90:330–339PubMedCrossRefGoogle Scholar
  32. 32.
    Herzum M, Huber SA, Weller R, Grebe R, Maisch B (1991) Treatment of experimental murine coxsackie B3 myocarditis. Eur Heart J 12 [Suppl D]:200–201PubMedCrossRefGoogle Scholar
  33. 33.
    Herzum M, Maisch B (1988) Humoral and cellular immune response in human myocarditis and dilated cardiomyopathy. Pathol Immunopathol Res 7:240–250PubMedCrossRefGoogle Scholar
  34. 34.
    Herzum M, Ruppert V, Küytz B, Jomaa H, Nakamura I, Maisch B (1994) Coxsackievirus B 3 infection leads to cell death of cardiac myocytes. J Mol Cell Cardiol 26:907–913PubMedCrossRefGoogle Scholar
  35. 35.
    Maisch B, Trostel-Soeder R, Stechemesser E, Berg PA, Kochsiek K (1982) Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin Exp Immunol 48:533–545PubMedGoogle Scholar
  36. 36.
    Maisch B, Bauer E, Cirsi M, Pankuweit S, Schönian U, Kochsiek K (1993) Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral protein in coxsackie virus B3 and B4 myocarditis-characterization and pathogenetic relevance. Circulation 87 [Suppl IV]:IV-49 — IV-65Google Scholar
  37. 37.
    Schultheiss H-P (1989) The significance of autoantibodies against the ADP/ATP carrier for the pathogenesis of myocarditis and dilated cardiomyopathy-clinical and experimental data. Springer Semin Immunopathol 11:15–30PubMedCrossRefGoogle Scholar
  38. 38.
    Kühl U, Melzner B, Schäfer B, Schultheiss HP, Strauer BE (1991) The Ca-channel as cardiac autoantigen. Eur Heart J 12(Suppl D) 99–104PubMedCrossRefGoogle Scholar
  39. 39.
    Limas CJ, Limas C (1991) Beta-adrenoceptor antibodies and genetics in dilated cardiomyopathy-an overview and review. Eur Heart J 12 [Suppl D]:175–177PubMedCrossRefGoogle Scholar
  40. 40.
    Wallukat G, Morwinski M, Kowal K, Förster A, Boewer V, Wollenberg A (1992) Autoantibodies against the ß-adrenergic receptor in human myocarditis and dilated cardiomyopathy: ß-adrenergic agonism without desensitization. Eur Heart J 17 [Suppl D]:178–181Google Scholar
  41. 41.
    Maisch B, Lotze U, Schneider J, Kochsiek K (1986) Antibodies to human sinus node in sick sinus syndrome. PACE 9:1101–1112PubMedCrossRefGoogle Scholar
  42. 42.
    Lotze U, Maisch B (1989) Humoral immune response to cardiac conducting tissue. Springer Semin Immunopathol 11:409–422PubMedCrossRefGoogle Scholar
  43. 43.
    Samsonov M, Nassonov E, Kostin S, Samk A, Alexandrova L, Masenko V, Naumov V, Mareev V, Shevlyagin S, Zhadanov V (1991) Serum neopterin-possible immunological marker of myocardial inflammation in patients with dilated heart muscle disease. Eur Heart J 12 (Suppl D):151–153PubMedCrossRefGoogle Scholar
  44. 44.
    Lyden DC, Feran M, Olszewski J, Job LP, Huber SA (1987) Coxsackievirus B-3 induced myocarditis: Effect of sex steroids on viremia and infectivity of cardiocytes. Am J Path 126:432–438PubMedGoogle Scholar
  45. 45.
    Weiler A, Huber S, Herzum M (1982) Genetics in viral heart disease. J Mol Genetics 27:332–338Google Scholar
  46. 46.
    Kandolf R, Hofschneider PH (1985) Molecular cloning of the genome of a cardiotropic coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. Proc Natl Acad Sci USA 82:4818–4822PubMedCrossRefGoogle Scholar
  47. 47.
    Mall G, Klingel K, Albrecht M, Seemann M, Rieger P, Kandolf R (1991) Natural history of coxsackievirus B3-induced myocarditis in ACCA/Sn mice: viral persistence demonstrated by quantitative in situ hybridization histochemistry. Eur Heart J 12 [Suppl D]:121–123PubMedCrossRefGoogle Scholar
  48. 48.
    Matsumori A, Kawai C (1989) Immunomodulating therapy in experimental myocarditis. Springer Semin Immunopathol 11:77–88PubMedCrossRefGoogle Scholar
  49. 49.
    Matsumori A, Yamada T, Kawai C (1991) Immunomodulating therapy in viral myocarditis: Effects of tumour necrosis factor, interleukin 2 and anti-interleukin-2 receptor antibody in an animal model. Eur Heart J 12 [Suppl D]:203–205PubMedCrossRefGoogle Scholar
  50. 50.
    Matsumori A (1992) Lessons from animal experiments in myocarditis. Herz 17:107–111PubMedGoogle Scholar
  51. 51.
    Woodruff JF, Woodruff JJ (1974) Involvement of T lymphocytes in the pathogenesis of coxsackievirus B3 heart disease. J Immunol 113:1726–1734PubMedGoogle Scholar
  52. 52.
    Huber SA, Job LP (1983) Cellular immune mechanisms in coxsackievirus group B, type 3 induced myocarditis in Balb/c mice. In: Spitzer John J (ed): Myocardial Injury. Plenum Publishing Corporation, New York, pp 491–508CrossRefGoogle Scholar
  53. 53.
    Huber SA, Lodge PA (1984) Coxsackie B-3 myocarditis in Balb/c mice: evidence for autoimmunity to myocyte antigens. Am J Pathol 116:21–29PubMedGoogle Scholar
  54. 54.
    Guthrie M, Lodge PA, Huber SA (1984) Cardiac injury in myocarditis induced by coxsackievirus group B, type 3 in Balb/c mice is mediated by Lyt2+ cytolytic lymphocytes. Cell Immunol 88:558–567PubMedCrossRefGoogle Scholar
  55. 55.
    Seko Y, Yagita H, Okumura K, Yazaki Y (1994) T-cell receptor Vb gene expression in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation 89:2170–2175PubMedCrossRefGoogle Scholar
  56. 56.
    Seko Y, Matsuda H, Kato K, Hashimoto Y, Yagita H, Okumura K, Yazaki Y (1993) Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Clin Invest 91:1327–1336PubMedCrossRefGoogle Scholar
  57. 57.
    Seko Y, Shinkai Y, Kawasaki A, Yagita H, Okumura K, Yazaki Y (1993) Evidence of perforin-mediated cardiac myocyte injury in acute murine myocarditis caused by coxsackievirus B3. J Pathol 170:53–58PubMedCrossRefGoogle Scholar
  58. 58.
    Yamada T, Matsumori A, Sasayama S (1994) Therapeutic effect of anti-tumor necrosis factor-α antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 89:846–851PubMedCrossRefGoogle Scholar
  59. 59.
    Huber SA, Polgar J, Schultheiss P, Schwimmbeck P (1994) Augmentation of pathogenesis of coxsackievirus B3 infections in mice by exogenous administration of inter — leukin-1 and interleukin-2. J Virol 68:195–206PubMedGoogle Scholar
  60. 60.
    Kishimoto C, Kuroki Y, Hiraoka Y, Ochiai H, Kurokawa M, Sasayama S (1994) Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage. Circulation 89:2836–2842Google Scholar
  61. 61.
    Lyden DC, Huber SA (1984) Aggravation of coxsackie virus B-3 induced myocarditis and increase in cellular immunity of myocyte antigens in pregnant Balb/c mice and animals treated with progesterone. Cell Immunol 87:462–472PubMedCrossRefGoogle Scholar
  62. 62.
    Lyden D, Olszewski J, Huber SA (1987) Influence of sex hormones on coxsackie virus group B, type 3 induced myocarditis in Balb/c mice. Eur Heart J 8 [Suppl. J]:389–391CrossRefGoogle Scholar
  63. 63.
    Huber SA, Pfaeffle B (199a) Differential Th1 and Th2 cell response in male and female BALB/c mice infected with coxsackievirus group B type 3. J Virol 68:5126-5132Google Scholar
  64. 64.
    Kilbourne ED, Wilson CB, Perrier D (1956) The induction of gross myocardial lesions by a coxsackie(pleurodynia) virus and cortisone. J Clin Invest 35:362–367PubMedCrossRefGoogle Scholar
  65. 65.
    Tomioka N, Kishimoto C, Matsumori A, Kawai C (1986) Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol 7:868–872PubMedCrossRefGoogle Scholar
  66. 66.
    Strom TB (1984) Immunosuppressive agents in renal transplantation. Kidney Int 26:353–362PubMedCrossRefGoogle Scholar
  67. 67.
    O’Connell JB, Reap Ea, Robinson JA (1986) The effect of cyclosporine on acute murine coxsackie B3 myocarditis. Circulation 73:353–355PubMedCrossRefGoogle Scholar
  68. 68.
    Mason JW, Billingham ME, Ricci DR (1980) Treatment of acute inflammatory myocarditis asssisted by endomyocardial biopsy. Amer J Cardiol 45:1037–1044PubMedCrossRefGoogle Scholar
  69. 69.
    Schultheiß HP, Kühl U, Janda I, Schanwell M, Strauer BE (1992) Immunosuppressive therapy in myocarditis. Herz 17:112–121PubMedGoogle Scholar
  70. 70.
    Maisch B, Schönian U, Hengstenberg C., Herzum M, Hufnagel G, Bethge C, Bittinger A, Neumann K (1994) Immunosuppressive treatment in autoreactive myocarditisresults from a controlled trial. Postgrad Med J 70 (Suppl. 1):S29–S34PubMedGoogle Scholar
  71. 71.
    Maisch B, Herzum M, Hufnagel, G, Bethge C, Schönian U (1995) Immunosuppressive treatment for myocarditis and dilated cardiomyopathy. Eur Heart J 16 [Suppl O]:153–161PubMedCrossRefGoogle Scholar
  72. 72.
    McKenna WJ, Davies MJ (1995) Immunosuppression for myocarditis N Engl J Med 333:312–313CrossRefGoogle Scholar
  73. 73.
    Cunnion RE, Parrillo JE (1995) Immunosuppressive therapy for myocarditis. N Engl J Med 333:1713PubMedCrossRefGoogle Scholar
  74. 74.
    Maisch B, Camerini F, Schultheiss H-P (1995) Immunosuppressive therapy for myocarditis. N Engl J Med 333:1713PubMedCrossRefGoogle Scholar
  75. 75.
    Cooper LT, Shabetai R (1995) Immunosuppressive therapy for myocarditis. N Engl J Med 333:1713–1714PubMedCrossRefGoogle Scholar
  76. 76.
    Mason JW, O’Connel JB, McManus BM (1995) Immunosuppressive therapy for myocarditis (authors reply). N Engl J Med 333:1714CrossRefGoogle Scholar
  77. 77.
    Billingham M (1993) Histology of myocarditis. In: Banatrala JE (Ed) Viral Infections of the heart. Arnold Publ, p 47Google Scholar
  78. 78.
    Parillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenno M, Schaer GL, Palmeri ST, Cannon RO, Ailing D, Wittes JT, Ferrans VJ, Rodriguez ER, Fauci AS (1989) A prospective randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321:1061–1068CrossRefGoogle Scholar
  79. 79.
    Maisch B (1990) Myocarditis. Current opinion in Cardiology 5:320–327CrossRefGoogle Scholar
  80. 80.
    Eckstein R, Mempel W, Bolte HD (1982) Reduced suppressor cell activity in congestive cardiomyopathy and in myocarditis. Circulation 65:1224–1229PubMedCrossRefGoogle Scholar
  81. 81.
    Maisch B, Herzum M, Hufnagel G, Schönian U (1996) Immunosuppressive and immunomodulatory treatment for myocarditis. Current Opinion in Cardiology 11:310–324PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1998

Authors and Affiliations

  • B. Maisch
  • G. Hufnagel
  • S. Pankuweit
  • M. Herzum
  • U. Schönian
  • C. Bethge
  • I. Portig
  • A. Wilke

There are no affiliations available

Personalised recommendations